Bigespas
Develops a Latrepirdine-derived drug candidate for Alzheimer’s disease
Highlights
- New on EvolcAdded 2026-11-13
About Bigespas
BIGESPAS develops Dimebon® DMB-I, a drug candidate for Alzheimer’s disease. The company holds a patent related to the DMB-I polymorph of Latrepirdine.
The company was established in 2020 as a UK-based private company. It started a Phase II trial in 2023 and completed a 28-week Phase II trial in 2025 involving patients with mild-to-moderate Alzheimer’s disease.
Product: Dimebon® DMB-I, a drug candidate for Alzheimer’s disease.
Jobs at Bigespas
More biotech & pharma companies
Biocaptiva
Develops cfDNA capture polymers and extraction kits for laboratories conducting liquid-biopsy research and testingBiocatalysts
Enzyme development, specialty enzyme products and contract manufacturing for food, beverage and industrial customersBiocortex
In-silico bridge trials mapping how microbiome differences change drug effects across populations, for pharma development teamsNew on EvolcBiods Consulting
Computational genomics consulting for pharma, biotech and research teams working with human genomic dataNew on EvolcBioflares
Far-red and near-infrared bioluminescent imaging reagents for in-vivo research in living animalsNew on EvolcBiointeractions
Develops biocompatible coatings and materials for medical device manufacturers and implant developersNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- TildaHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.